Rigel Pharmaceuticals (RIGL)
NASDAQ:RIGL
Want to see RIGL full AI Analyst Report?
Top Page
Rigel
(NASDAQ:RIGL)
Select Model
Select Model
Rating:69Neutral
Price Target:
$31.00
▼(-4.41% Downside)
Action:Downgraded
Date:05/21/26
RIGL scores highest on financial performance, reflecting a notable profitability and cash-flow turnaround, and is supported by reiterated 2026 guidance and continued product growth. The overall score is held back by weak technical positioning versus key moving averages and lingering uncertainty around the durability of earnings/cash generation, with mixed corporate-event impact (VEPPANU upside vs. Lilly termination).
Positive Factors
Revenue & Profitability Turnaround
Rigel has delivered a durable commercial uplift with TTM revenue up sharply and a marked swing to profitability, driven by portfolio sales (TAVALISSE, REZLIDHIA, GAVRETO). This structural revenue and margin improvement supports reinvestment, product expansion, and de-risks sole-product concentration over the medium term.
Negative Factors
Loss of Lilly Partnership
Termination removes a major development/commercial partner and eliminates expected milestone/royalty streams, forcing Rigel to absorb development costs and program risk for the RIPK1 asset. This increases resource needs and program-level uncertainty, and could slow or reprioritize pipeline plans over many quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Profitability Turnaround
Rigel has delivered a durable commercial uplift with TTM revenue up sharply and a marked swing to profitability, driven by portfolio sales (TAVALISSE, REZLIDHIA, GAVRETO). This structural revenue and margin improvement supports reinvestment, product expansion, and de-risks sole-product concentration over the medium term.
Read all positive factors
Rigel (RIGL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$553.77M
Dividend YieldN/A
Average Volume (3M)402.13K
Price to Earnings (P/E)1.5
Beta (1Y)1.95
Revenue Growth47.61%
EPS Growth854.73%
CountryUS
Employees162
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)20.07
Shares Outstanding18,502,080
10 Day Avg. Volume324,978
30 Day Avg. Volume402,125
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.97
Price to Sales (P/S)2.62
P/FCF Ratio10.18
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit2.09
Enterprise Value/Ebitda4.46
Forecast
1Y Price Target
$59.33Price Target Upside82.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)3.99
Revenue Forecast (FY)$282.83M
Rigel Business Overview & Revenue Model
Company Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the trea...
How the Company Makes Money
Rigel makes money primarily from (1) net product sales of TAVALISSE in the United States, where it commercializes the drug and recognizes revenue from sales to wholesalers/specialty distributors and other customers, net of typical biopharma deduct...
Rigel Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 04, 2026
Earnings Call Sentiment Positive
The call conveys a generally positive commercial and strategic outlook: strong top-line product growth (26% YoY overall; 31% YoY for TAVALISSE and REZLIDHIA), clear 2026 guidance and a pathway to full-year profitability, alongside promising early clinical data for R289 and expanded international partner revenues. Offsetting risks include rising operating expenses, a modest decline in quarterly net income and cash, seasonal Q1 reimbursement headwinds, a slower-growing GAVRETO franchise, and the termination of the Lilly collaboration for the RIPK1 asset (creating program-level uncertainty). On balance, the highlights—robust product sales growth, maintained guidance, pipeline progress and improved financing flexibility—outweigh the lowlights.Positive Updates
Strong Quarterly Net Product Sales Growth
Net product sales of $54.9M in Q1 2026, up 26% year-over-year (+$11.3M vs Q1 2025), driven by across‑portfolio strength and improving demand in March.
Negative Updates
Decline in Quarterly Net Income
Net income was $8.7M in Q1 2026, down from $11.4M in Q1 2025 (≈23.7% decrease year-over-year), reflecting higher operating costs despite revenue growth.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Quarterly Net Product Sales Growth
Net product sales of $54.9M in Q1 2026, up 26% year-over-year (+$11.3M vs Q1 2025), driven by across‑portfolio strength and improving demand in March.
Read all positive updates
Company Guidance
Management reiterated 2026 guidance for total revenues of $275–$290 million, comprising net product sales of $255–$265 million and contract revenues of $20–$25 million, and affirmed their expectation to deliver positive net income for the full year. In Q1 they reported total revenue of $58.8M (net product sales $54.9M, +26% YoY) including TAVALISSE $37.3M (+31%), GAVRETO $9.6M (+7%) and REZLIDHIA $8.0M (+31%), plus $3.9M collaboration revenue; net product sales were recorded net of $20.5M of discounts/allowances. Q1 cost of product sales was ~$4.6M, total costs and expenses were $46.9M (vs. $40.6M prior year), income before taxes $11.7M and net income $8.7M (vs. $11.4M). Balance sheet and financing items noted: cash, cash equivalents and short‑term investments of $146.7M (down from $155.0M at 12/31/25), repayment of a $40M term loan and establishment of a $40M revolving credit facility (option to increase to $60M) with $8M drawn; guidance excludes any assumed revenues from the Lilly collaboration.Rigel Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
74
Positive
Cash Flow
76
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 299.77M | 294.28M | 179.28M | 116.88M | 120.24M | 149.24M |
| Gross Profit | 279.95M | 274.66M | 160.63M | 109.77M | 118.49M | 148.15M |
| EBITDA | 131.28M | 131.56M | 28.51M | -16.98M | -53.87M | -11.29M |
| Net Income | 364.23M | 367.02M | 17.48M | -25.09M | -58.57M | -17.91M |
Balance Sheet | ||||||
| Total Assets | 504.61M | 513.59M | 163.98M | 117.22M | 134.28M | 167.33M |
| Cash, Cash Equivalents and Short-Term Investments | 146.68M | 154.96M | 77.32M | 56.93M | 58.21M | 124.97M |
| Total Debt | 45.72M | 53.30M | 59.97M | 60.58M | 41.55M | 30.57M |
| Total Liabilities | 104.71M | 122.11M | 160.69M | 145.87M | 147.90M | 136.95M |
| Stockholders Equity | 399.90M | 391.48M | 3.29M | -28.64M | -13.62M | 30.37M |
Cash Flow | ||||||
| Free Cash Flow | 79.27M | 75.66M | 31.07M | -20.74M | -74.21M | 5.25M |
| Operating Cash Flow | 79.27M | 75.66M | 31.47M | -5.74M | -73.76M | 5.88M |
| Investing Cash Flow | -89.79M | -92.36M | 4.13M | -4.30M | 72.78M | -80.04M |
| Financing Cash Flow | -10.80M | 601.00K | -11.64M | 18.37M | 6.55M | 62.67M |
Rigel Technical Analysis
Positive
32.43
Price Trends
29.33
Positive
31.13
Negative
34.44
Negative
Market Momentum
0.23
Negative
52.43
Neutral
65.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RIGL, the sentiment is Positive. The current price of 32.43 is above the 20-day moving average (MA) of 29.41, above the 50-day MA of 29.33, and below the 200-day MA of 34.44, indicating a neutral trend. The MACD of 0.23 indicates Negative momentum. The RSI at 52.43 is Neutral, neither overbought nor oversold. The STOCH value of 65.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RIGL.
Rigel Risk Analysis
Rigel disclosed 59 risk factors in its most recent earnings report. Rigel reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rigel Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $553.77M | 1.51 | 147.03% | ― | 47.61% | 854.73% | |
53 Neutral | $843.97M | ― | -18.64% | ― | 123.12% | 86.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $355.68M | ― | -232.50% | ― | -43.96% | -78.31% | |
51 Neutral | $292.77M | -1.34 | -35.74% | ― | 146.03% | -0.87% | |
45 Neutral | $326.01M | -1.88 | -486.41% | ― | 395.85% | 21.44% |
* Healthcare Sector Average
RIGL
Rigel
29.93
8.08
36.98%
LXRX
Lexicon Pharmaceuticals
1.91
1.17
158.11%
VSTM
Verastem
3.71
-2.40
-39.28%
RGNX
RegenXBio
6.08
-3.45
-36.20%
BCYC
Bicycle Therapeutics
4.20
-4.34
-50.82%
Rigel Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Rigel Shareholders Approve Equity Plans and Board Slate
Positive
May 20, 2026
At its May 14, 2026 annual meeting, Rigel Pharmaceuticals’ stockholders approved amendments to the company’s 2018 Equity Incentive Plan and 2000 Employee Stock Purchase Plan, adding 500,000 and 360,000 shares, respectively, to the pool...
Business Operations and StrategyProduct-Related Announcements
Rigel Secures Global Rights to VEPPANU Breast Cancer Therapy
Positive
May 12, 2026
On May 11, 2026, Rigel Pharmaceuticals entered into a license agreement with Arvinas and Pfizer to obtain exclusive worldwide rights to develop, manufacture and commercialize VEPPANU (vepdegestrant) and related products, consolidating Rigel’...
Business Operations and Strategy
Rigel Regains Rights as Eli Lilly Ends Collaboration
Negative
Apr 21, 2026
On April 16, 2026, Rigel Pharmaceuticals received notice that Eli Lilly is terminating their 2021 license and collaboration agreement, which will become effective June 15, 2026. The deal had granted Lilly exclusive global rights to develop and com...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.